DEA Takes Emergency Action Against Dangerous Synthetic Drug

The Drug Enforcement Administration (DEA) has implemented an emergency scheduling of bromazolam, a synthetic benzodiazepine, due to a significant increase in its trafficking and abuse across the United States. This action places bromazolam under Schedule I of the Controlled Substances Act, acknowledging its lack of accepted medical use and its high potential for abuse. Consequently, the manufacture, distribution, possession, and other handling of bromazolam are now subject to strict administrative, civil, and criminal penalties.

The DEA’s move aims to address a rapidly evolving threat posed by novel psychoactive substances. Bromazolam has been identified as a key component in counterfeit Xanax tablets and has become one of the most frequently detected benzodiazepines in illicit drug seizures analyzed by DEA laboratories. This emergency scheduling is designed to close critical gaps in regulatory control, disrupt the availability of the drug, and equip law enforcement and public health officials with the necessary tools to combat its spread.

The abuse of designer benzodiazepines, including bromazolam, has been linked to severe adverse health effects. These can include slurred speech, loss of coordination (ataxia), altered mental states, and potentially life-threatening respiratory depression. Of particular concern is the growing trend of co-abuse of these designer benzodiazepines with opioids, which exacerbates the risks associated with the ongoing opioid crisis in the United States. By placing bromazolam in Schedule I, the DEA is taking decisive action to protect communities from the dangers of emerging synthetic drugs.

Article by Mel Anara, based upon information from the Drug Enforcement Administration

---